INTRODUCTION {#s1}
============

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two most common hepatotropic viruses responsible for majority of acute and chronic hepatitis worldwide \[[@R1]\]. Over 350 million individuals chronically infected with HBV are at high risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) \[[@R2]\]. HBV is a small hepatotropic DNA virus. Serological markers for HBV infection include HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc. HBsAg is the hallmark of infection while HBcAb is an indicator of past or present hepatitis B infection \[[@R3]\]. The prevalence of HBV infection varies markedly throughout the world. 45% of HBV-infected individuals live in highly endemic areas, which include China, Southeast Asia, sub-Saharan Africa and the Amazon Basin \[[@R4], [@R5]\]. Chronic infection with HCV is another major risk factor for the development of HCC worldwide. Unlike HBV, HCV is a positive-sense single-stranded RNA virus of the family *Flaviviridae* \[[@R6]\]. The highest prevalence of HCV has been reported in Africa and the Middle East, with a lower prevalence in the Americas, Australia and Northern and Western Europe \[[@R7]\].

Systemic lupus erythematous (SLE) is a classic systemic autoimmune diseases characterized by chronic inflammation, autoantibodies production, complement activation and immune-complex deposition, resulting in tissue and organ damage. SLE is occurring predominantly in young women with the female: male ratio of 10:1. Overall, the incidence of SLE is higher in African, American and Asian populations than in Caucasians \[[@R8]\]. The cause of SLE is not fully understood, but it is believe to involve hormonal, environmental, genetic and immunological factors \[[@R9]\].

Autoimmune disease is closely related to viral infection since it can be induced or triggered by viruses. For example, EBV was found to be associated with SLE and RA \[[@R10]\]. In contrast, some viral infections can also protect individuals from specific autoimmune diseases. CMV and EBV infection were shown to play a protective role in type 1 diabetes \[[@R11], [@R12]\]. Although the potential association between HBV and SLE has been studied for decades it still remains controversial. HCV infection is associated with many autoimmune processes \[[@R13]\], but the association between HCV infection and SLE disease has not been clearly established. Therefore, the current study was designed to evaluate the prevalence of hepatitis virus infection among SLE patients through meta-analysis of published studies.

RESULTS {#s2}
=======

Characteristics of the included studies {#s2_1}
---------------------------------------

A flow diagram of studies selection is shown in Figure [1](#F1){ref-type="fig"}. A total of 2446 articles met the defined search criteria. Further screen of their titles and abstracts identified the potentially relevant articles. Finally, 22 studies were selected for the meta-analysis \[[@R14]--[@R33]\].

![Flowchart depicting the selection of studies for the meta-analysis](oncotarget-08-102437-g001){#F1}

As listed in Table [1](#T1){ref-type="table"}, 11 case-control studies, published between 1997 and 2016, were identified to analyze HBV infection state using HBsAg. All of the 11 studies were from the Asian. Of those, 8 studies were from China, one from China Taiwan, one from Japan and one from Israel. 4 studies were retrospective design, and 7 were prospective. Altogether, 127 cases of HBV infection in 9333 SLE patients were reported. Among 203329 control individuals, 16392 cases of HBV infection were identified. Controls included healthy subjects in 4 studies, non-SLE inpatients in another 4 studies, and 3 studies used rheumatoid arthritis (RA) patients as controls.

###### Characteristics of included studies (HBsAg)

  Study                 Publication year   Country         Type of study   SLE patients(n)   Controls(n)   Control description           Matching and adjustments   HBsAg detection         NOS score   Reference
  --------------------- ------------------ --------------- --------------- ----------------- ------------- ----------------------------- -------------------------- ----------------------- ----------- -----------
  Wang F, et al.,       2016               China           Prospective     346               12779         Healthy subjects              Age and sex                NA                      6           14
  Sui M, et al.         2014               China           Retrospective   155               3122          Non-autoimmune population     Age and sex                ELISA/CMIA              7           15
  Watanabe R, et al.    2014               Japan           Retrospective   1128              3580          RA                            NA                         NA                      6           16
  Zhao J, et al.        2010               China           Retrospective   859               155222        Non-SLE inpatients            Age and sex                NA                      8           17
  Zheng BR, et al.      2010               China           Retrospective   379               209           Physical examination takers   NA                         NA                      5           18
  Lu CL, et al.         1997               Taiwan, China   Prospective     173               692           Healthy subjects              Age and sex                Radioimmunoassay kits   8           19
  Cao YX, et al.        2002               China           Prospective     131               582           Healthy controls              Age and sex                Elisa                   6           20
  Wang S, et al.        2016               China           Retrospective   866               1795          Healthy controls              Age and sex                Elisa                   7           21
  Wu CX, et al.         2005               China           Retrospective   176               194           RA                            Age and sex                NA                      5           22
  Qiu N, et al.         2011               China           Prospective     102               64            Non-SLE inpatients            NA                         Elisa                   5           23
  Gendelman O, et al.   2016               Israel          Retrospective   5018              25090         Non-SLE inpatients            Age and sex                NA                      6           24

Table [2](#T2){ref-type="table"} showed the 7 studies published between 1997 and 2016, which analyzed the past or present hepatitis B infection using HBcAb status. Among these studies, 3 studies were from China, 2 studies were from Israel, one from China Taiwan and one from Japan. 4 studies selected controls from healthy subjects, 1 study used non-SLE inpatients and 2 studies used rheumatoid arthritis (RA) patients as controls.

###### Characteristics of included studies (HBcAb)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                Publication year   Country         Type of study   SLE patients(n)   Controls(n)   Control description                                                                    Matching and\   HBcAb detection             NOS score   Reference
                                                                                                                                                                                                 adjustments                                             
  -------------------- ------------------ --------------- --------------- ----------------- ------------- -------------------------------------------------------------------------------------- --------------- --------------------------- ----------- -----------
  Wang F, et al.,      2016               China           Prospective     346               12779         Healthy subjects                                                                       Age and sex     NA                          6           14

  Watanabe R, et al.   2014               Japan           Retrospective   248               703           RA                                                                                     NA              NA                          6           16

  Ram M, et al.        2008               Israel          Prospective     117               140           Individuals without inflammatory, autoimmune disease or history of chronic infection   Age and sex     Elisa                       7           25

  Berkun Y, et al.     2009               Israel          Prospective     120               140           Without known inflammatory or autoimmune disease                                       Age and sex     BioPlex 2200 Multiplexed\   7           26
                                                                                                                                                                                                                 Immunoassay method                      

  Lu CL, et al.        1997               Taiwan, China   Prospective     173               222           Healthy subjects                                                                       Age and sex     Radioimmunoassay kits       8           19

  Wu CX, et al.        2015               China           Retrospective   176               194           RA                                                                                     Age and sex     NA                          5           22

  Qiu N, et al.        2001               China           Prospective     102               64            Non-SLE inpatients                                                                     NA              Elisa                       5           23
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

9 studies published, between 2000 and 2017, were included to analyze the prevalence of HCV infection among SLE patients. All of the 9 studies were conducted either in Asia or South America. 7 studies were retrospective studies and 2 were prospective. The quality of included studies ranged from moderate to good, varying from six to eight points, based on NOS scoring system. The detail characteristics of the included studies are listed in Table [3](#T3){ref-type="table"}.

###### Characteristics of included studies (HCV)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Publication year   Country   Type of study   SLE patients (*n*)   Controls (*n*)   Control description       Matching and\   HCV detection                                 NOS score   Reference
                                                                                                                                           adjustments                                                               
  --------------------------- ------------------ --------- --------------- -------------------- ---------------- ------------------------- --------------- --------------------------------------------- ----------- -----------
  Feng, H., et al.            2006               China     Prospective     92                   58               Normal control people     Age and sex     PCR                                           6           27

  Mahroum, N., et al.         2017               Israel    Retrospective   5018                 25090            Controls without SLE      Age and sex     NA                                            6           28

  Ramos-Casals, M., et al.    2000               Spain     Prospective     134                  200              Volunteer blood donors    Age and sex     Elisa, RIBA, PCR                              6           29

  Agmon-Levin, N., et al.     2009               Israel    Prospective     108                  236              Healthy controls          Age and sex     Elisa                                         7           30

  Mercado, U., et al.         2005               México    Prospective     110                  300              Blood donors              NA              Elisa, RIBA, PCR                              6           31

  Wang,S., et al.             2016               China     Retrospective   844                  1348             Blood donors              Age and sex     Elisa                                         7           21

  Berkun, Y., et al.          2009               Israel    Prospective     120                  140              Non-autoimmune controls   Age and sex     BioPlex 2200 Multiplexed Immunoassay method   7           26

  Mowla, K. and E. Hajiani,   2008               Iran      Prospective     109                  110              Healthy donors            Age and sex     Elisa, PCR                                    8           32

  Costa, C.A., et al.         2002               Brazil    Prospective     91                   8867             Volunteer blood donors    Age and sex     Elisa, PCR                                    6           33
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The prevalence of HBV infection in patients with SLE {#s2_2}
----------------------------------------------------

We identified 11 case-control results that associated SLE with HBsAg positivity indicative of HBV infection. Of those, 10 studies from Asia reported relatively lower rate of HBsAg positivity in patients diagnosed with SLE compared with the control population, whereas one study from Israel did not support this observation \[[@R24]\]. In a meta-analysis of these studies, the pooled odds ratio was (OR: 0.28; 95% CI: 0.13, 0.61) in a random effect model for HBsAg positive rate in SLE patients compared with control population. However, we detected significant heterogeneity among the studies (*I^2^* = 92%, *P* \< 0.00001), which might be due to the study from Israel. If this study was further excluded, the adjusted OR of HBsAg in patients with SLE was 0.24 (95% CI: 0.17, 0.33). No significant heterogeneity was observed after adjustment (*I^2^* = 32%, *P* = 0.15) (Figure [2A](#F2){ref-type="fig"}). The funnel plot and egger\'s test were used to assess the publication bias of the included studies. The funnel plot was symmetric (Figure [2B](#F2){ref-type="fig"}) and the egger\'s test showed no significant publication bias (*P* = 0.869).

![Meta-analysis of HBsAg positivity rate in SLE patients and controls\
(**A**) Forest plot of the meta-analysis for the HBsAg positive rate in patients with SLE versus controls, OR, odds ratio; CI, confidence Interval. (**B**) Funnel plots showing lack of bias in 11 studies measuring the rate of HBsAg positivity in SLE patients and controls.](oncotarget-08-102437-g002){#F2}

Moreover, we conducted additional meta-analysis to evaluate the infection status of HBV in SLE patients using the HBcAb positive rate. For this, 7 studies with 1282 participants were included in pooled analysis. The risk of HBcAb-positive rate in patients with SLE was 3.13-fold lower (pooled OR 0.32, 95% CI 0.23--0.46) than that in the control population. There was a moderate heterogeneity between studies with an *I^2^* of 53% (*P* = 0.05) (Figure [3A](#F3){ref-type="fig"}). If the study from Wang, F., et al. 2016 was excluded, the adjusted OR of HBsAg in patients with SLE was 0.4 (95% CI: 0.31, 0.50). No significant heterogeneity was observed after adjustment (*I^2^* = 0%, *P* = 0.56) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The funnel plot was symmetric (Figure [3B](#F3){ref-type="fig"}) and the egger\'s test showed no significant publication bias (*P* = 0.145).

![Meta-analysis comparing the rate of HBcAb positivity in SLE patients and controls\
(**A**) Forest plot shows the HBcAb positive rate in patients with SLE versus controls, OR, odds ratio; CI, confidence Interval. (**B**) Funnel plots showed no publication bias in 7 studies measuring HBcAb positive rate in SLE patients and controls.](oncotarget-08-102437-g003){#F3}

The prevalence of HCV infection in patients with SLE {#s2_3}
----------------------------------------------------

We also conducted a meta-analysis to evaluate the risk of HCV infection in SLE patients. 9 case control studies reported the prevalence of HCV infection in SLE patients. Of those, 8 studies showed that the HCV positive rate was higher in SLE patients compared with the control population. In the meta-analysis of all 9 studies, the pooled OR was 2.91 (95% CI: 2.21, 3.84) in a fixed-effects model (Figure [4A](#F4){ref-type="fig"}), There was no statistically significant heterogeneity among studies (*I^2^* = 18%; *P* = 0.28). The subgroup analysis showed no significant change in both the PCR group and non-PCR group ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Omission of any single study did not significantly change the overall OR ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). No evident asymmetry of plots was seen in the funnel plots (Figure [4B](#F4){ref-type="fig"}) and the Egger\'s test showed no significant publication bias (*P* = 0.512).

![Meta-analysis of the prevalence rate for HCV in SLE patients and controls\
(**A**) Forest plot showing the prevalence of HCV infection in patients with SLE versus controls. OR, odds ratio; CI, confidence Interval. (**B**) Funnel plots showed no publication bias in 9 studies examining HCV prevalence rate in SLE patients and controls.](oncotarget-08-102437-g004){#F4}

DISCUSSION {#s3}
==========

The infection of HBV and HCV has posed a major public-health problem worldwide and is the major cause leading to chronic liver disease. Ineffective antiviral immune responses have been implicated as the critical factors leading to development of chronic HBV and HCV infections \[[@R34]\]. Although, viral infections and autoimmunity are closely associated their association often remains controversial. For example, some studies proposed that HBV or HCV infection represent a triggering factor for development of systemic autoimmune diseases \[[@R13], [@R34]\]. In contrast, it has also been suggested that HBV infection can afford a protection against development of autoimmune disorders \[[@R11], [@R35]\]. SLE is a classical autoimmune disease, which similarly to HBV affects many people worldwide, however the relation between SLE and hepatitis virus infection remains unknown. Here, we present a meta-analysis to explore the prevalence of HBV or HCV in SLE patients. The results of our meta-analysis point to a low prevalence of HBV infection in patients with SLE in highly endemic areas. The risk of HBsAg positive rate in SLE patients was lower when compared with the control group, suggesting a protective role of pro-inflammatory environment in SLE against HBV infection. This is in contrast with HCV infections, which manifest high prevalence in SLE patients compared to controls.

In this meta-analysis, the pooled OR was 0.28 for HBsAg positive rate in SLE patients compared with control population, however a significant heterogeneity was observed among the studies. Particularly, a sole study conducted in Israel revealed a different conclusion. Upon exclusion of this study, the adjusted OR of HBsAg in patients with SLE was 0.21, and no significant heterogeneity was then observed. However, our analyses suggest that a positive rate of HBsAg in SLE patients may vary among different endemic regions. Of interest, in highly endemic Asian areas, HBsAg positive rate was lower in patients with SLE than that of the control group. Moreover, to evaluate the prevalence of HBV infection in SLE patients we performed additional meta-analysis in which the level of anti-HBcAb was analysed. The presence of anti-HBcAb in serum is indicative of previous or current HBV infections. Consistent with our previous findings, our results confirmed that the rate of circulating anti-HBcAb was also lower in patients with SLE compared to the control group. These analyses therefore suggested that SLE autoimmunity exerted a protection against HBV infections. The mechanism of lower prevalence of HBV in SLE patients is still unclear. One explanation is that cytokines including IFN-α, IL-6, TNF-α are over-expressed in SLE patients. IFN-α can induce transcription of IFN responsive genes through Jak-STATs signaling pathway, which plays a critical role in the innate immune response against viral infections \[[@R36]\]. IFN-α is commonly used for the treatment of chronic hepatitis B (CHB) patients \[[@R37]\]. IL-6 production is also increased in SLE patients and involved in lupus pathogenesis \[[@R38]\]. Interestingly, IL-6 is a key cytokine for early control HBV infection through suppression of HBV transcription, antigen expression and replication \[[@R39]\]. Therefore enhanced production of IL-6 in SLE patients may have an inhibitory effect on HBV infection.

Another possibility is the association of androgen deficiency observed in SLE with HBV infection \[[@R40]\]. As two large prospective studies have shown, HBV carriers exhibited higher androgen concentrations than healthy controls \[[@R41], [@R42]\], therefore androgen deficiency observed in SLE patients may prevent the establishment of chronic HBV infection.

Unlike HBV, this meta-analysis demonstrated that the prevalence of HCV in SLE patients was higher than in the control group. HCV and HBV belong to different viral families (Flaviviridae and Hepadnoviridae, respectively). They are characterized by different genetic structures and epidemic features. At present, the reason for the high prevalence of HCV in SLE patients remains unclear. One explanation for higher frequency of HCV infection in patients with SLE compared to the control population could be attributed immunological dysregulation observed among SLE patients, and this may be further compounded by immunosuppressive therapies.

The present study has some limitations. First, most of the studies included in these meta-analyses were conducted in Asia where the rates of CHB are high. Additional studies regarding the percentage of HBV infection among SLE patients in other regions, such as Europe and America, should be performed in the future. Second, several studies relied on HCV diagnosis using only a traditional Elisa approach, rather that HCV RNA analysis, which is a more sensitive and accurate detection method. Nevertheless, to our knowledge, this is the first comprehensive meta-analysis to evaluate up-to-date observational studies that reported a relationship between SLE and HBV or HCV infections.

In conclusion, this meta-analysis revealed a relationship between HBV/HCV infection and SLE. Interestingly, we identified a low prevalence of HBV infection and a high prevalence of HCV infection in patients with SLE. However, the precise mechanism by which this occurs remains obscure. Further mechanistic studies are necessary to determine the role of SLE in HBV/HCV infection.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

The following databases were used in this study: PubMed/MEDLINE, EMBASE, as well as two major Chinese databases, China National Knowledge Infrastructure (CNKI) and Wanfang Data. The keywords or subject headings used were ''hepatitis B or HBV or HBsAg or HBcAb or Hepatitis C or HCV'' and ''systemic lupus erythematosus or SLE'', from the earliest date available to June 30, 2017. Non-English publications were also included. The bibliographies of selected original studies, reviews, and relevant abstracts were screened.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

For each eligible study, the title and/or abstract were screened independently by two authors. Any disagreement was resolved by discussion between the authors. We included studies that met the following inclusion criteria: (1) an original case--control study (retrospective, prospective) comparing HBV or HCV infection rate between SLE patients and controls; (2) study reporting the absolute numbers of cases and controls as well as the positive rate of HBV or HCV infection; (3) Described the serological markers for defined HBV and HCV infection. Abstracts, reviews, letters, case reports, and studies that did not provide sufficient data were excluded.

Quality assessment {#s4_3}
------------------

The methodological quality of the included studies was assessed by New castle Ottawa Scale (NOS). NOS, a star system allowing a semi-quantitative assessment of nonrandomized study quality for observed studies, contained eight items that were categorized into three major components, including selection, comparability, and exposure (case-control studies). NOS assigns a maximum of 4 points for selection, 2 for comparability, and 3 for exposure or outcome. We assigned NOS scores of 1--3, 4--6, and 7--9 for low-, intermediate-, and high-quality studies, respectively.

Data extraction {#s4_4}
---------------

We obtained the following data from each article by using a standardized protocol: last name of the first author, study name, publication year, country where the study was conducted, prospective or retrospective nature of the study, diagnostic method of HBV infection, number of patients with HBV or HCV infection in SLE and control groups as well as the details of the controls used in the studies.

Statistical analysis {#s4_5}
--------------------

The meta-analysis was performed using Review Manager 5.3 software from the Cochrane Collaboration (London, UK). We calculated the odds ratio (OR) and 95% confidence intervals (CI) to assess the prevalence of HBV and HCV infection in the SLE group compared with the control group. In the forest plots, OR \> 1 represented a risk effect and OR \< 1 indicated a protective effect. The heterogeneity of the studies was evaluated using the Chi-square test and *I^2^* statistic. The fixed-effects model was used if the heterogeneity was insignificant (Chi-square test *P* ≥ 0.10 and *I^2^* ≤ 50%), while the random-effects model was preferred if significant heterogeneity was found (Chi-square test *P* \< 0.10 or *I^2^* \> 50%). The funnel plot and Egger\'s test were used to analyze publication bias.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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